Abstract: SA-PO503
Spexin: Is It Another Bystander or a New Biomarker in Diabetic Kidney Disease?
Session Information
- Diabetic Kidney Disease: Basic - III
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 601 Diabetic Kidney Disease: Basic
Authors
- Cha, Jin Joo, Korea University, Ansan, Korea (the Republic of)
- Cha, Dae R., Korea University, Ansan, Korea (the Republic of)
- Ghee, Jungyeon, Korea University, Ansan, Korea (the Republic of)
- Yoo, Ji ae, Korea University, Ansan, Korea (the Republic of)
- Lim, Jeong-Taek, Korea University, Ansan, Korea (the Republic of)
- Joa, Jungmin, Korea University, Ansan, Korea (the Republic of)
- Kang, Young Sun, Korea University, Ansan, Korea (the Republic of)
Background
Spexin is a highly conserved active neuropeptide that has been recently identified in the involvement of controlling appetite and energy balance. Although few is known regarding to the role of spexin, spexin level was noted to be significantly lower in obese and diabetic patients. Recent study has shown that spexin mRNA was significantly detected in human kidney tissue. Therefore, we investigated the expression of spexin in diabetic kidney disease in clinical and experimental model.
Methods
Serum samples from patients who were diagnosed as type 2 diabetes were examined for circulating spexin level using commercially available ELISA kit (Spexin/neuropeptide Q(NQP)). Serum and renal expression of spexin was examined in experimental mice models; ü1) normal control, 2) db/db mice, 3) fat chow diet induced obesity mice and 4) non-diabetic UUO-induced mice.
Results
Total 89 diabetic patients participated in the study. The circulating spexin level was significantly increased in patients on dialysis (both peritoneal and hemodialysis) compared to patients with estimated GFR ≥60 ml/min/1.73m2. In diabetic patients with chronic kidney disease stage 1 to 3, spexin level was significantly increased in patients with overt proteinuria (urine protein to creatinine ratio). There was significant correlation between serum spexin and proteinuria, however no correlations were observed in age, gender, BMI, blood glucose, lipid profiles and HOMA-IR or estimated GFR with serum spexin level. Spexin was detectable in serum and kidney tissue of murine models. In experimental mice of obese type 2 diabetes (db/db), serum spexin level was significantly increased, whereas its renal expression was not significantly different compared to normal and obstructed kidney control.
Conclusion
The spexin expression in the kidney from experimental mice and circulating spexin level in diabetic patients may indicate that spexin may be a biomarker of diabetic kidney disease. However, further study is needed to elucidate the specific role and mechanism of spexin in metabolic kidney disease.